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A B S T R A C T
Hepatocellular carcinoma (HCC) has emerged as one of the most common malignancies worldwide. It is asso-
ciated with a high mortality rate, as evident from its increasing incidence and extremely poor prognosis. The
deubiquitinating enzyme 26S proteasome non-ATPase regulatory subunit 14 (PSMD14) has been reported to act
as an oncogene in several human cancers. The present study aimed to reveal the functional significance of
PSMD14 in HCC progression and the underlying mechanisms. We found that PSMD14 was significantly upre-
gulated in HCC tissues. Overexpression of PSMD14 correlated with vascular invasion, tumor number, tumor
recurrence, and poor tumor-free and overall survival of patients with HCC. Knockdown and overexpression
experiments demonstrated that PSMD14 promoted proliferation, migration, and invasion in HCC cells in vitro,
and facilitated tumor growth and metastasis in vivo. Mechanistically, we identified PSMD14 as a novel post-
translational regulator of GRB2. PSMD14 inhibits degradation of GRB2 via deubiquitinating this oncoprotein in
HCC cells. Furthermore, pharmacological inhibition of PSMD14 with O-phenanthroline (OPA) suppressed the
malignant behavior of HCC cells in vitro and in vivo. In conclusion, our findings suggest that PSMD14 could serve
as a novel promising therapeutic candidate for HCC.
1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malig-
nancy. It is the third leading cause of cancer-related deaths worldwide,
with approximately 600,000 deaths per year [19]. Although systemic
therapy for HCC, such as surgical resection, transarterial chemoembo-
lization (TACE), local ablation, intra-arterial infusion chemotherapy,
and molecular targeted therapy, has markedly advanced, the 5-year-
survival rate remains less than 12%, owing to distant metastasis and
recurrence [12,29]. Moreover, a large number of risk factors are asso-
ciated with the initiation and progression of HCC. Therefore, it is es-
sential to gain insight into the underlying mechanisms of HCC initiation
and progression to design novel and effective therapies, with an aim to
improve the prognosis of patients with HCC.
The deubiquitinase (DUB) 26S proteasome non-ATPase regulatory
subunit 14 (PSMD14, also known as RPN11 and POH1), belongs to the
JAMM domain metalloprotease family of DUBs and is a component of
19S regulatory cap in 26S proteasome. PSMD14 has been demonstrated
to play important roles in regulating several biological processes, in-
cluding protein stability [21], transcriptional regulation [23], aggre-
some clearance and disassembly [14], double-strand DNA break repair
[8], senescence [9], embryonic stem cell differentiation [6], cellular
viability [11], drug resistance [18,25] and metastasis [34]. Recently,
overexpression of PSMD14 was reported in several kinds of human
cancers, such as HCC, multiple myeloma, esophageal squamous cell
carcinoma, and breast cancer, where it was associated with poor clin-
ical outcomes in patients [17,25,30,33,34]. PSMD14 acts as an onco-
gene that promotes tumor progression by deubiquitinating different
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protein substrates. For instance, in esophageal squamous cell carci-
noma, PSMD14 targets epithelial-mesenchymal transition (EMT)-asso-
ciated transcription factor SNAIL for deubiquitination, thus stabilizing
it and promoting tumor cell migration and invasion in vitro and tumor
metastasis in vivo [34]. Similarly, in HCC, PSMD14 deubiquitylates
transcriptional factor E2F1, increases its stability, and strengthens its
downstream pro-survival signals, including upregulation of survivin
and FOXM1 expression, thereby facilitating HCC growth [30]. Ad-
ditionally, PSMD14 enhances metastatic capacity of HCC cells by deu-
biquitinating TGF-β receptors and caveolin 1 (CAV1), as well as nega-
tively regulating the turnover of TGF-β receptors [31]. However, other
mechanism of the contribution of PSMD14-mediated deubiquitination
in the progression of HCC remains elusive.
In the present study, we examined the expression levels of PSMD14
in HCC tissues and analyzed the relationship of PSMD14 expression
with clinicopathological features and prognosis of patients with HCC.
Furthermore, we observed that PSMD14 promoted proliferation, mi-
gration, and invasion in vitro and tumor growth metastasis in vivo by
stabilizing GRB2 protein. To summarize, our study reveals a previously
unknown mechanism of the role of PSMD14 in HCC progression,
wherein GRB2 expression is posttranslationally upregulated by
PSMD14, resulting in tumor growth and metastasis.
2. Materials and methods
2.1. Tissue collection
Fifty-four pairs of HCC and corresponding adjacent normal liver
tissues were obtained from patients with HCC who underwent hepa-
tectomy between 2013 and 2017 at Zhongshan Hospital of Xiamen
University. None of the patients received interventional therapy, che-
motherapy, or sorafenib treatment before the surgery. Tissue samples
were obtained and immediately frozen in liquid nitrogen and stored at
−80 °C for further detection. Written informed consent for this research
was obtained from all patients. The informed consent and experimental
procedures were approved by the ethics committee of the Zhongshan
Hospital of Xiamen University in accordance with the World Medical
Association Declaration of Helsinki.
2.2. Cell culture
HEK293T, PLC/PRF/5, and Hep3B cells were acquired from the
American Type Culture Collection (ATCC; Manassas, VA, USA). SMMC-
7721 and MHCC-97h cells were obtained from the United Innovation of
Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province
and Zhongshan Hospital of Fudan University, respectively. The au-
thentication of these cell lines was performed via comparisons with the
STR database. The cells were cultured in high glucose Dulbecco's
modified Eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS; Serana, Germany) at 37 °C in a humidified incubator with
5% CO2 in the air.
2.3. Immunohistochemistry
Tissues were fixed with 10% neutral formalin, embedded in par-
affin, and 4-μm thick sections were prepared. In brief, im-
munohistochemistry (IHC) staining was performed as follows. The
sections were deparaffinized, hydrated, and soaked in 3% H2O2 for
20min at room temperature, and subsequently incubated with anti-
PSMD14 (1:1000, ab10800, Abcam) and anti-GRB2 (1:1000, 10800-1-
AP, Proteintech) antibodies at 4 °C overnight. The slides were incubated
with biotinylated goat anti-rabbit antibodies for 1 h and stained with
diaminobenzidine (DAB; Maixin Biotechnology, Fuzhou, China), fol-
lowed by counterstaining with hematoxylin (Maixin Biotechnology). In
order to avoid bias, the IHC-stained sections were evaluated by two
clinical pathologists who were blinded to the experimental data. In
brief, we counted 100 cells randomly at 200×microscopic fields and
classified them into five groups according to the percentage of positive
staining cells in HCC tissues as follows: 0=negative; 1–3=1–25%;
4–6=26–50%; 7–9=51–75%; 10–12=≥76%. The score ranging
from 0 to 6 was considered as a low-expression group, whereas the
score ranging from 7 to 12 was considered as a high-expression group.
2.4. Overexpression of PSMD14
Adenovirus-expressing vector and PSMD14-Flag (containing three
Flag tags) were purchased from Vigene Biosciences Corporation (Jinan;
Shandong Province, China). The cells were infected with adenovirus-
expressing vector or PSMD14-Flag. After 48 h, the cells were used to
detect the following.
2.5. Generation of knockdown cell lines
HCC cells were stably infected with shRNAs against PSMD14
(shPSMD14-1: GACACAGCAGAACAAGTCT, shPSMD14-2: CACTCAGC
AGAGCTTTGAA), and GRB2 (shGRB2-1: GGTACAAGGCAGAGCTTAA,
shGRB2-2: GAGCCAAGGCAGAAGAAAT), or scramble control in the
pLV-shRNA-puro lentiviral background. Lentiviral particles were pro-
duced in HEK293T cells following the manufacturer's instructions
(Inovogen Tech. Co., Beijing, China). Lentiviral particles were collected
48 h after transfection. The cells were infected with viral supernatants
using polybrene (8 μg/mL). The stable cells were selected after 48 h
using 5 μg/mL puromycin (InvivoGen) for one week.
2.6. Colony formation assay
The HCC cells were seeded at a density of 2× 103 cells per well into
6-well culture plates in triplicate and then cultured for two weeks.
Colonies formed were fixed with 4% paraformaldehyde for 20min at
room temperature. These were subsequently stained with 1% crystal
violet for 30min.
2.7. Cell proliferation detection
The HCC cells were seeded at a density of 2× 103 cells per well into
96-well culture plates in triplicate. The proliferation of cells was as-
sessed in three independent experiments using the CCK-8 (cell counting
kit-8) assay (Dojindo; Beijing, China) at indicated time points according
to the manufacturer's instructions. After 48 h, the cells were incubated
with CCK-8 solution for 1.5 h. The absorbance of the colored solution
was measured at 450 nm using a spectrophotometer.
2.8. Transwell assay
In order to detect cell migration and invasion, the indicated cells,
mixed with 100 μL serum-free DMEM, were seeded onto an 8-μm pore
polycarbonate membrane with or without pre-coated Matrigel in the
upper chamber as per the manufacturer's instructions (Corning
Incorporated; New York, NY, USA). The bottom chamber was filled
with 600 μL DMEM, supplemented with 10% FBS. After 24 h incuba-
tion, the migratory or invasive cells were fixed with 4% paraf-
ormaldehyde for 20min at room temperature, and subsequently stained
with 1% crystal violet for 30min. Cells in 10 randomly selected views
were counted.
2.9. Mass spectrometry
The PLC/PRF/5 cells were incubated with 10 μM MG132 for 6 h.
The cell lysates were immunoprecipitated with anti-PSMD14 antibodies
(4197, Cell Signaling) overnight. Subsequently, these were conjugated
with protein Dynabeads Protein G for immunoprecipitation (10001D,
Invitrogen) for an additional incubation of 2 h. Gel electrophoresis was
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run, following which in-gel digestion was performed to prepare samples
for subsequent proteomic analysis. The LC-MS/MS analysis of the
samples to identify proteins interacting with PSMD14 was conducted by
College of Life Sciences, Xiamen University, as described below.
2.10. Protein extraction and western blotting
Cells were lysed in radioimmunoprecipitation assay (RIPA) lysis
buffer (Beyotime; Beijing, China). After quantification using a BCA
protein assay kit (Thermo), protein samples were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). These
were then transferred onto polyvinylidene difluoride (PVDF) mem-
branes (Millipore). Membranes were blocked in 5% non-fat milk (Bio-
Rad) for 1 h at room temperature and then incubated with anti-PSMD14
(4197, Cell Signaling), anti-β-actin (3700, Cell Signaling), or anti-GRB2
(ab32037, Abcam) antibody, followed by incubation with anti-rabbit or
anti-mouse secondary antibodies conjugated to horseradish peroxidase
(HRP, Jackson). Immunoreactive proteins were subsequently visualized
using the enhanced chemiluminescence (ECL) detection system
(Millipore).
2.11. Co-immunoprecipitation assay
HEK293T cells were seeded into 10-cm plates and transfected with
indicated plasmids. Total proteins were extracted in co-im-
munoprecipitation (co-IP) lysis buffer (Beyotime, Beijing, China). The
cell lysates were incubated with anti-GFP (ab32146, Abcam) or anti-HA
(3724, Cell Signaling) antibody and Dynabeads Protein G for im-
munoprecipitation (10001D, Invitrogen) at 4 °C overnight. The beads
were then washed thrice with lysis buffer and the immunoprecipitates
were collected for Western blot analysis. For endogenous co-IP, lysates
were incubated with 3mg anti-PSMD14 (4197, Cell Signaling) or anti-
GRB2 (ab32037, Abcam) antibody or negative control IgG (2729, Cell
Signaling) overnight, followed by conjugation with protein Dynabeads
Protein G for immunoprecipitation (10001D, Invitrogen) for an addi-
tional 2 h. After washing the beads thrice with lysis buffer, the im-
munoprecipitated proteins were collected for Western blot analysis.
2.12. In vivo deubiquitination assay
Indicated plasmids were transiently transfected into HEK293T cells
for 48 h. After incubation with 10 μM MG132 (Selleck) for 6 h, the cells
were harvested and lysed in the denature lysis buffer. HA-ubiquitinated
FLAG-GRB2 was immunoprecipitated using the anti-FLAG M2 affinity
gel (A2220, Sigma Aldrich). The FLAG-GRB2 protein was purified and
immunoblotted with antibody against HA (5017, Cell Signaling).
Endogenous GRB2 was immunoprecipitated using the anti-GRB2
antibody (ab32037, Abcam) under denaturing conditions. The en-
dogenous GRB2 protein was purified and subsequently collected for
immunoblotting with antibody against ubiquitin (3936, Cell Signaling).
2.13. Animal study
A xenograft mouse model was constructed using 6-week-old male
BALB/c athymic nude mice. A total of 2× 107 cells were injected
subcutaneously into the right flank of the nude mice. Approximately
seven days later, tumor size was measured using a vernier caliper.
Tumor volumes were calculated using formula V=½
(length×width2). To check the effect of PSMD14 on tumor metastasis,
2× 106 cells were injected into the tail vein of male BALB/c athymic
nude mice. Each group contained 7 mice and these mice were sacrificed
eight weeks after injection. The lung tissues were fixed in 10% neutral
formalin, embedded in paraffin, and cut into 3-μm thick sections.
Hematoxylin and eosin (H&E) staining was performed in all lung tissues
according to the standard protocol. The number of pulmonary metas-
tasis nodules was counted under a microscope (Leica, Germany). All
animal experiments were approved by the Animal Care and Use
Committee of the Xiamen University.
2.14. Statistical analysis
All statistical analyses were performed using the SPSS software
(Version 19.0). Data are presented as mean ± standard deviation (SD)
and three independent experiments were performed. Differences in the
results among groups were compared using Student's t-test or multi-way
analysis of variance (ANOVA) test. The relationship between PSMD14
expression and clinical features of patients with HCC was analyzed
using Chi-squared test. Spearman's rank correlation was used to ex-
amine the correlation between PSMD14 and GRB2 expression. The
correlation between PSMD14 or GRB2 expression and prognosis of
patients with HCC was analyzed using the Kaplan-Meier survival test
and the log-rank test. Differences were considered significant for p-va-
lues less than 0.05.
3. Results
3.1. PSMD14 is highly expressed in HCC tissues
We first examined the expression levels of PSMD14 in 54 pairs of
HCC and corresponding adjacent normal tissues using IHC assay. As
shown in Figure 1A and 63.0% (34/54) HCC tissues expressed con-
siderably higher PSMD14 levels than those expressed by adjacent
normal liver tissues. To determine whether PSMD14 expression was
related to the HCC progression, we analyzed the association between
PSMD14 expression and clinicopathological features in these patients.
Statistical analysis revealed a significant correlation between PSMD14
expression and vascular invasion (p=0.003), tumor number
(p=0.028), and recurrence (p < 0.001) in the patients. However,
PSMD14 expression was not associated with other factors, including
age, gender, tumor size, differentiation, liver cirrhosis, serum HBV, and
alpha-fetoprotein (AFP) level. Moreover, Kaplan-Meier and log-rank
test analyses indicated that HCC patients with high PSMD14 expression
had significantly decreased overall survival and tumor-free survival
(Fig. 1B and C) than those with low PSMD14 expression. For further
confirmation of these results, we analyzed The Cancer Genome Atlas
(TCGA) data using the UALCAN online tool (http://ualcan.path.uab.
edu/index.html). Consistent with our findings, these results showed
that PSMD14 was significantly higher in primary HCC tissues than that
in normal tissues (Fig. 1D). Additionally, the Kaplan-Meier analysis
using the Kaplan-Meier Plotter online tool (http://kmplot.com/
analysis/) demonstrated that patients with high PSMD14 expression
exhibited significantly shorter overall survival compared with those
having low PSMD14 expression (p=5.6e–05, HR=2.07 (1.44–2.98),
Fig. 1E). Collectively, these data suggest that upregulation of PSMD14
was associated with malignant progression of HCC.
3.2. PSMD14 promotes HCC cell proliferation in vitro and tumor growth in
vivo
To assess the functional role of PSMD14 in development and pro-
gression of HCC, we performed a knockdown of PSMD14 expression in
SMMC-7721, PLC/PRF/5, and MHCC-97h cells using two shRNAs that
targeted different sites within PSMD14 (Fig. 2A). The proliferation of
HCC cells expressing PSMD14 shRNAs was significantly suppressed
compared with that in the control cells (Fig. 2B). Similarly, colony
formation analysis revealed that depletion of PSMD14 significantly
inhibited the colony formation ability of HCC cells (Fig. 2C). Con-
versely, PSMD14 was overexpressed in PLC/PRF/5 and SMMC-
7721 cells (Fig. 2D). CCK-8 and colony formation assays demonstrated a
pro-proliferative effect of PSMD14 overexpression on HCC cells (Fig. 2E
and F). The reciprocal effects of knockdown and overexpression of
PSMD14 in vitro suggested that PSMD14 enhanced the proliferation
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ability of HCC cells. The protein p53 has been demonstrated to be in-
volved in PSMD14-mediated cell proliferation [33]. Nevertheless, we
found that knockdown of PSMD14 led to an obvious decrease in the
proliferation capacity of Hep3B cells (p53 deficient), indicating that
PSMD14 promoted the proliferation of HCC cells via a p53-independent
manner (Supplementary Fig. 1A and 1B).
To further confirm the proliferation potential of PSMD14 in vivo, the
control and PSMD14-silenced MHCC-97h cells were subcutaneously
injected into nude mice. The results showed that tumors formed by
PSMD14 stable knockdown cells were much smaller than those formed
by the control cells (Fig. 2G). Additionally, the tumor weight of the
group was markedly lower than that of the control group (Fig. 2H).
Collectively, these data demonstrated that PSMD14 promoted HCC
growth both in vitro and in vivo.
3.3. PSMD14 promotes HCC cell migration and invasion in vitro and tumor
metastasis in vivo
The correlation between PSMD14 expression and vascular invasion
(Table 1) indicated that PSMD14 could be involved in HCC metastasis.
We then validated the effects of PSMD14 on in vitro migratory and in-
vasive behaviors of HCC cells. Transwell assay demonstrated that
knockdown of PSMD14 dramatically decreased the migration and in-
vasion capacity of SMMC-7721, PLC/PRF/5, and MHCC-97h cells as
compared with that of control groups (Fig. 3A). Conversely, the cell
migration and invasion ability was significantly enhanced by ectopic
overexpression of PSMD14 in SMMC-7721 and PLC/PRF/5 cells
(Fig. 3B).
To further validate the metastasis potential of PSMD14 in vivo, the
control and PSMD14-silenced MHCC-97h cells were injected into the
tail vein of nude mice to establish a metastasis model. It was observed
that the knockdown of PSMD14 resulted in significantly decreased
number and size of pulmonary metastatic nodules in mice (Fig. 3C). To
conclude, these results demonstrated that PSMD14 facilitated cell mi-
gration and invasion, and tumor metastasis both in vitro and in vivo.
3.4. PSMD14 interacts with and deubiquitinates GRB2
To reveal the underlying mechanism of PSMD14 in regulating HCC
progression, we performed a mass spectrometry analysis to identify
global proteins that could co-immunoprecipitate with PSMD14. A total
of 710 proteins were identified to potentially interact with PSMD14.
Growth factor receptor-bound protein 2 (GRB2) is a key molecule in
intracellular signal transduction and critical for cell cycle progression,
motility, morphogenesis, and angiogenesis [13]. Moreover, GRB2 sig-
naling has been implicated in tumorigenesis and cancer progression
[20,24,27]. In this context, the interactome data of GRB2 from a pre-
vious study reported that PSMD14 is a potential interacting protein of
GRB2 [4]. However, to date, whether GRB2 stability is regulated by
DUBs has remained elusive. Interestingly, we found that GRB2 poten-
tially interacted with PSMD14. A co-IP assay was utilized to validate the
interaction between PSMD14 and GRB2 in HEK293T cells. The re-
ciprocal co-IP experiment was subsequently performed to further define
the interaction (Fig. 4A). Furthermore, the interaction between en-
dogenous GRB2 and PSMD14 was confirmed by co-IP using PLC/PRF/
5 cell lysate treated by proteasome inhibitor MG132 (Fig. 4B).
We then determined the regulatory relationship between PSMD14
and GRB2. The knockdown of PSMD14 significantly decreased the
GRB2 protein expression in HCC cells (Fig. 4C). Moreover, xenografts in
nude mice with MHCC-97h cells carrying PSMD14 knockdown dis-
played poor staining for GRB2 relative to that by control xenografts
(Fig. 4D). However, depletion of PSMD14 could not have an effect on
Fig. 1. Upregulation of PSMD14 predicts poor
clinical outcome in patients with HCC.
A. The expression of PSMD14 in 54 pairs of HCC and
corresponding adjacent normal liver tissues was
examined by the immunohistochemistry (IHC)
assay. A representative image is shown.
B and C. Kaplan-Meier survival analysis of the
overall survival (B) and tumor-free survival (C) in
the HCC patients based on PSMD14 expression. The
low expression patients (n=
20) showed an expression value of HCC tissues less
than the normal tissues, while the high expression
patients (n=34) showed the expression value of
HCC tissues larger than normal tissues.
D. The PSMD14 mRNA levels in normal and primary
HCC tumor tissues from the TCGA database. E.
Kaplan-Meier survival analysis of the HCC patients
from the TCGA database according to PSMD14
mRNA expression. The high expression patients
showed the expression value of> 3rd quantile of
PSMD14 expression, and the low expression pa-
tients showed the expression value<3rd quartile of
PSMD14 expression.
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GRB2 mRNA expression levels (Supplementary Fig. 2A), indicating that
PSMD14 modulated GRB2 expression through a post-transcriptional
mechanism. To examine whether PSMD14 stabilized GRB2 protein, we
checked the effect of both PSMD14 knockdown and overexpression on
the stability of endogenous GRB2 protein by performing cycloheximide
(CHX) pulse-chase assay. For this, HCC cells with PSMD14 alteration
were treated with CHX to block protein synthesis at the indicated time,
and subsequently, the GRB2 protein levels were analyzed using western
blotting. It was observed that knockdown of PSMD14 accelerated the
degradation of GRB2 protein in MHCC-97h cells (Fig. 4E), whereas
PSMD14 overexpression could strikingly extend the half-life of GRB2
protein levels in PLC/PRF/5 cells (Fig. 4F). Since GRB2 is an important
regulator of ERK, AKT, and STAT3 signaling pathways [2,7,26], we
next investigated whether these signaling pathways were affected by
PSMD14. We demonstrated that phosphorylation levels of AKT, ERK,
and STAT3 were markedly decreased following PSMD14 knockdown
(Supplementary Fig. 2B). Moreover, an in vivo ubiquitination assay
validated that the ubiquitination level of GRB2 was significantly in-
creased by PSMD14 silencing (Fig. 4G), thereby protecting GRB2 from
degradation. We next determined which types of polyubiquitin mod-
ifications of GRB2 protein were affected by PSMD14-mediated deubi-
quitination. For this, HEK293T cells were transfected with FLAG-GRB2
and GFP-PSMD14, and each one of the different ubiquitins (K11-, K48-,
or K63-only ubiquitin-HA), separately. Next, FLAG-GRB2 proteins in
the lysates were purified and subjected to Western blot analysis using
an anti-HA antibody. K48- and K63-linked ubiquitination on GRB2 was
substantially reduced by the overexpression of PSMD14 (Fig. 4H).
Previous reports demonstrated that the C120 and H113 sites and the
JAMM motif of PSMD14 are critical for the deubiquitinating enzymatic
activity of PSMD14 [30]. Moreover, we found that the mutant PSMD14
could interact with GRB2 (Supplementary Fig. 2C), and only ectopic
expression of wild-type PSMD14, but not the PSMD14 mutants C120S
or H113Q or△JAMM (deletion of JAMMmotif), upregulated the GRB2
protein levels (Supplementary Fig. 2D), suggesting that the deubiqui-
tinating enzymatic activity of PSMD14 was essential for regulating the
expression of GRB2. Taken together, these data demonstrated that
PSMD14 mediated GRB2 deubiquitination and stabilization.
3.5. PSMD14 exerts oncogenic effects through GRB2
We next examined whether PSDM14 regulated HCC progression in a
GRB2-dependent manner. Endogenous GRB2 was silenced by transfec-
tion of lentiviral particles expressing GRB2 shRNAs in HCC cells. The
knockdown efficacy was validated by immunoblot analysis (Fig. 5A).
CCK-8 and colony formation assays demonstrated that depletion of
GRB2 suppressed cell proliferation compared with that in the control
groups. Moreover, knockdown of GRB2 inhibited HCC cell migration
and invasion, as evident from results of the transwell assays (Fig. 5D).
In addition, we rescued the expression of GRB2 in PSMD14-silenced
HCC cells. The restoration of GRB2 expression abolished the inhibition
of the proliferative, migratory, and invasive abilities induced by
PSMD14 depletion (Fig. 5E and F, Supplementary Fig. 3A and 3B). In-
terestingly, rescuing the activation of AKT, ERK, or STAT3 signaling
alone also partially attenuated the PSMD14 silencing-mediated sup-
pressive effects (Supplementary Fig. 3C and 3D). Taken together, these
findings suggested that PSMD14 functions upstream of GRB2 to reg-
ulate HCC progression.
3.6. PSMD14 expression is positively correlated with GRB2 in HCC tissues
and predicts poor clinical outcome
Based on our experimental findings on HCC cell lines that PSMD14
could increase GRB2 expression, we performed IHC staining of GRB2 on
the same set of HCC tissues to determine the relevance of regulation of
GRB2 expression by PSMD14 in the patients. As shown in Fig. 6A, GRB2
expression was considerably higher in HCC tissues than that in the
adjacent normal liver tissues. Furthermore, we found that the
Fig. 2. PSMD14 promotes HCC growth in vitro and in vivo.
A. SMMC-7721, PLC/PRF/5 and MHCC-97h cells were infected with lentiviral particles expressing shRNAs targeting PSMD14. The knockdown efficacy was detected
by the W
estern blot analysis.
B. The CCK-8 assay was used to detect the proliferation of control and PSMD14 knockdown HCC cells.
C. Colony formation assay was used to detect the proliferation of control and PSMD14 knockdown HCC cells.
D. SMMC-7721 and PLC/PRF/5 cells were infected with the adenovirus expressing vector or PSMD14-Flag (contains three Flag tags). The overexpression efficacy was
detected by the Western blot analysis.
E. The CCK-8 assay was used to detect the proliferation of control and PSMD14 overexpressing SMMC-7721 and PLC/PRF/5 cells.
F. Colony formation assay was used to detect the proliferation of control and PSMD14 overexpressing SMMC-7721 and PLC/PRF/5 cells.
G. Scramble control or PSMD14 knockdown MHCC-97h cells were subcutaneously injected into nude mice for the observation of tumor growth.
H. The tumor weight of xenograft from the different groups (G) was calculated. *p < 0.05,**p < 0.01 and **p < 0.001. Data represent at least three independent
sets of experiment.
Table 1
Association between PSMD14 expression and clinicopathological features of
HCC.
Clinicopathological features PSMD14 high PSMD14 low X2 p value
Age(yr)d
< 53 19(55.9%) 8(40.0%) 1.271 0.260
≥53 15(44.1%) 12(60.0%)
Gender
Male 28(82.4%) 16(80.0%) 0.046 0.830
Female 6(17.6%) 4(20.0%)
Tumor size
< 5 cm 9(26.5%) 8(40.0%) 1.069 0.301
≥5 cm 25(73.5%) 12(60.0%)
Vascular invasion
Yes 26(76.5%) 7(35.0%) 9.113 0.003*
No 8(23.5%) 13(65.0%)
Differentiation
Poor
Moderate
Well
5(14.7%)
28(82.4%)
1 (2.9%)
0(0.0%)
19(95.0%)
1(5.0%)
3.317 0.190
Liver cirrhosis statusa
No 13(44.8%) 13(72.2%) 3.372 0.066
Yes 16(55.2%) 5(27.8%)
Serum HBV level (Iu/mL)b
< 1000 23(69.7%) 11(55.0%) 1.170 0.279
≥1000 10(30.3%) 9(45.0%)
Serum AFP level (ng/mL)
< 200 17(50.0%) 13(65.0%) 1.148 0.284
≥200 17(50.0%) 7(35.0%)
Tumor number
Multiple 15(44.1%) 3(15.0%) 4.804 0.028*
Single 19(55.9%) 17(85.0%)
Recurrencec
Yes 19(79.2%) 4(23.5%) 12.508 <0.001*
No 5(20.8%) 13(76.5%)
*Statistically significant, P < 0.05.
a Seven missing data points.
b One missing data points.
c Thirteen missing data points.
d The mean age of the total 54 cases of patients was 53 years.
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Fig. 3. PSMD14 facilitates HCC invasion and metastasis in vitro and in vivo.
A. The representative images of transwell assay for the control and PSMD14 knockdown HCC cells. The cells were counted under a microscope in five randomly
selected fields.
B. The representative images of transwell assay for the control and PSMD14 overexpressing SMMC-7721 and PLC/PRF/5 cells. The cells were counted under a
microscope in five randomly selected fields.
C. The representative microscopic images of pulmonary metastatic lesions at eight weeks after the injection of indicated MHCC-97h cells into the tail vein of nude
mice. The number and diameter of lung metastatic tumors in each group were determined. *p < 0.05 and **p <
0.01. Data represent at least three independent sets of the experiment.
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overexpression of PSMD14 in HCC tissues was accompanied by upre-
gulation of GRB2 as compared with that in the normal liver tissues
(Fig. 6B, p < 0.0001, R=0.479). Moreover, we observed a strong
positive correlation between PSMD14 and GRB2 expression in the same
HCC samples (Fig. 6C, p < 0.0001, R2= 0.3987).
To investigate the prognostic value of GRB2 expression, the
Fig. 4. PSMD14 deubiquitinates and stabilizes GRB2.
A. The GFP-PSMD14 plasmid was co-transfected with HA-GRB2 plasmid into HEK293T cells. The cell lysates were immunoprecipitated to pull down GRB2 or
PSMD14 by the anti-HA or anti-GFP antibodies, respectively, and subjected to immunoblotting.
B. Endogenous GRB2 proteins were immunoprecipitated with anti-GRB2 antibody and then analyzed by immunoblotting (up panel). Endogenous PSMD14 proteins
wereimmunoprecipitated with anti-PSMD14 antibody and then analyzed by immunoblotting (down panel). The IgG antibody was used as the control.
C. The expression levels of GRB2 in the control and PSMD14 knockdown HCC cells were determined by the Western blot.
D. Immunohistochemical staining for GRB2 and PSMD14 in tumor xenografts of nude mice developed by PSMD14 knockdown of the MHCC-97h cells.
E. The control and PSMD14 knockdown MHCC-97h cells were treated with CHX (100 μg/mL) for the indicated time points. The cell lysates were subjected to
immunoblotting (left panel) and the GRB2 expression was quantified by Quantity One software (right panel). **p < 0.01.
F. Control and PSMD14 overexpressing PLC/PRF/5 cells were treated with CHX (100 μg/mL) for the indicated time points. The cell lysates were subjected to
immunoblotting (left panel) and GRB2 expression was quantified by Quantity One software (right panel). *p < 0.05.
G. The control and PSMD14 knockdown MHCC-97h cells were treated with MG132 at 10 μM for 8 h. The cell lysates were then immunoprecipitated with anti-GRB2
antibody, and the immunocomplexes were immunoblotted with anti-GRB2 and anti-ubiquitin antibodies.
H. HEK293T cells overexpressing FLAG-GRB2, GFP-PSMD14, and HA-tagged different forms of ubiquitin were treated with MG132 (10 μM) for 8 h. The cell lysates
were immunoprecipitated by using anti-FLAG M2 affinity gel. The ubiquitination levels of GRB2 were detected using anti-HA antibody.
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association of GRB2 protein expression with clinical outcomes of HCC
patients was analyzed. The Kaplan–Meier analysis revealed that pa-
tients with high GRB2 expression in HCC tissues had a shorter overall
postoperative survival time than those with low expression
(p=0.0281, Fig. 6D). Additionally, the effects of the combination of
GRB2 and PSMD14 expression on outcomes are shown in Fig. 6E.
PSMD14 & GRB2 high group had a worse outcome than the PSMD14 &
GRB2 low group (p=0.0241). Taken together, our results suggested
that the overexpressed PSMD14 and GRB2 could serve as potential
prognostic markers for patients with HCC.
3.7. Therapeutic effects of PSMD14 inhibitor OPA on the malignant
behavior of HCC cells
Recently, a metallopeptidase inhibitor O-phenanthroline (OPA) was
found to inhibit PSMD14 activity, thereby suppressing cell growth and
Fig. 5. PSMD14 exerts oncogenic effects through GRB2.
A. SMMC-7721, PLC/PRF/5, and MHCC-97h cells were infected with lentiviral particle expressing shRNAs targeting GRB2. The knockdown efficacy was detected by
the Western blot analysis.
B. The CCK-8 assay was used to detect the proliferation of control and GRB2 knockdown HCC cells.
C. Colony formation assay was used to detect the proliferation of control and PSMD14 knockdown HCC cells.
D. The representative images of transwell assay on for the control and PSMD14 knockdown HCC cells. The cells were counted under a microscope in five randomly
selected fields.
E. GRB2 abolished the proliferation inhibition induced by PSMD14 knockdown in MHCC-97h cells as confirmed by CCK-8 assays.
F. GRB2 abolished the migration and invasion inhibition induced by PSMD14 knockdown in MHCC-97h cells as confirmed by transwell assays. *p < 0.05 and
**p < 0.01. Data represent at least three independent experiments.
Fig. 6. PSMD14 expression is positively correlated
with GRB2 in HCC tissues.
A. The representative images of im-
munohistochemical staining of PSMD14 and GRB2
in the same normal and HCC tissues.
B. Correlation study of PSMD14 and GRB2 in HCC
tissues. Statistical analyses were performed with the
Chi-square test. R, Pearson correlation coefficient.
C. Representative images of immunohistochemical
staining of GRB2 in HCC tissues with different ex-
pression levels of PSMD14. Scatter diagram ex-
hibited a positive correlation of PSMD14 and GRB2
in HCC tissues by IHC.
D. Survival analysis of HCC patients by Kaplan-
Meier plots and log-rank tests. The patients were
categorized into the high and low expression groups
of GBR2 based on IHC staining.
E. Survival analysis of HCC patients by Kaplan-
Meier plots and log-rank tests. The patients were
categorized into the high and low expression groups
of GBR2 and PSMD14 based on IHC staining.
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overcoming drug resistance [25]. We next evaluated the therapeutic
effect of OPA on HCC. SMMC-7721 and Hep3B cells were treated with
different concentrations of OPA. The results of CCK-8 and colony for-
mation assays showed that the treatment of OPA inhibited the pro-
liferation of HCC cells in a concentration-dependent manner (Fig. 7A
and B). Furthermore, the migration and invasion of SMMC-7721 and
Hep3B cells was markedly reduced upon treatment with different
concentrations of OPA when compared to the DMSO-treated cells
(Fig. 7C). Moreover, we examined whether OPA affected the HCC
growth and metastasis in vivo. It was demonstrated that treatment of
OPA resulted in an obvious decrease in tumor growth and metastasis in
nude mice (Fig. 7D–G). Taken together, these data indicated a strong
inhibitory effect of PSMD14 inhibitor OPA on HCC progression.
4. Discussion
In the present study, our results demonstrated that PSMD14 was
overexpressed in HCC tissues, and was significantly associated with
vascular invasion, tumor number, and tumor recurrence. Furthermore,
it was found that the upregulation of PSMD14 expression predicted
shorter overall and tumor-free survival time in patients with HCC.
Consistent with these results, the high PSMD14 expression in patients
with HCC of the TCGA database suggested a trend of poor prognosis.
Previous studies revealed a significant negative correlation between
PSMD14 expression and survival time of patients with different cancers,
including HCC, breast cancer, esophageal cancer, multiple myeloma,
and colorectal cancer [17,25,33,34]. Our results are in accordance with
these studies, implying that PSMD14 could be a potential prognostic
predictor for patients with these cancers.
As a deubiquitinase, overexpression of PSMD14 has been found to
contribute to cancer progression through deubiquitinating and stabi-
lizing diverse substrates. Here, our findings showed that PSMD14 pro-
moted in vitro proliferation, migration, and invasion of HCC cells, and
facilitated tumor growth and metastasis in vivo. Considering that GRB2
played a critical role in enhancing the malignant behavior of cancer
cells [13], and the ubiquitination of GRB2 remains elusive, we revealed
the mechanism underlying PSMD14-mediated GRB2 regulation. We
found that PSMD14 increased the protein levels of GRB2; however, it
did not influence the mRNA levels of GRB2. Moreover, the downstream
signaling of GRB2 was affected by PSMD14 knockdown. The knock-
down of PSMD14 accelerated the degradation of GRB2 protein, whereas
PSMD14 overexpression could strikingly extend the half-life of GRB2
protein levels. Additionally, the ubiquitination level of GRB2 was sig-
nificantly increased by depletion of PSMD14. PSMD14 belongs to the
JAMM domain metalloproteases and functions as a K63-specific deu-
biquitinase [17]. However, both K48- and K63-linked ubiquitination on
GRB2 were substantially reduced by overexpression of PSMD14. The
decreased K48-linked ubiquitination on GRB2 by PSMD14 was con-
siderably obvious than the K63-linked ubiquitination, indicating that an
indirect mechanism was involved in the regulation of PSMD14-medi-
ated K48-linked ubiquitination of GRB2. A recent study reported a si-
milar phenomenon that both K48 and K63 poly-ubiquitin chains of
TGFBR1 and TGFBR2 proteins could be reduced by PSMD14. PSMD14
modulated K48 poly-ubiquitin chains of TGFBR1 and TGFBR2 in a ly-
sosomal degradation-dependent manner through deubiquitinating
CAV1 [32]. Based on this research, we speculated that PSMD14 could
affect some intermediate proteins that could regulate K48-linked ubi-
quitination on GRB2. The exact molecular mechanism by which
PSMD14 regulates the K48-linked ubiquitination on GRB2 warrants
further investigation.
Tumor metastasis is the primary cause of poor clinical outcomes in
patients with HCC [3]. Snail1 is a zinc-finger transcription factor and
crucial for cellular movement during cancer metastasis by inducing
epithelial-mesenchymal transition (EMT) [5]. The upregulation of
Snail1 expression is related to poor prognosis of patients with cancer
[15]. Snail1 directly represses epithelial markers, such as E-cadherin
and claudins, by forming a transcriptional complex with epigenetic
modifiers, such as DNA methylation transferases (DNMTs), EZH2, and
G9a [10,28]. It has been reported that PSMD14 is critical for Snail1-
induced migration, invasion, and the EMT process in esophageal cancer
cells. PSMD14 was identified to associate with Snail1, which could
induce deubiquitination and stabilization of Snail1 protein [34]. The
cytokine transforming growth factor β (TGF-β) signaling induces EMT
and enhances the metastatic potential of cancer cells through induction
of Snail1 expression [1]. Interestingly, PSMD14 could deubiquitinate
TGF-β receptors and CAV1, and subsequently suppress lysosome
pathway-mediated turnover of TGF-β receptors in HCC cells, which is
critical for TGF-β signaling [32]. GRB2 is an adaptor protein that in-
teracts with phosphorylated TGF-β receptor. A recent study demon-
strated that Snail1 expression was upregulated by GRB2 overexpression
and was further enhanced by TGF-β stimulation in lung cancer cells
[20]. Our results showed that PSMD14 could stabilize GRB2 and up-
regulate its expression, suggesting that PSMD14 might also increase
Snail1 expression through GRB2. Based on these findings, we suspected
that EMT-related transcription factor Snail1 could be crucial for
PSMD14-induced metastasis via GRB2 and TGF-β signaling.
Recently, specific, small-molecule inhibitors against PSMD14, in-
cluding OPA, 8-thioquinoline (8TQ), and capzimin, have been identi-
fied. Some inhibitors have been shown to suppress cancer progression.
OPA blocks cellular proteasome function, induces apoptosis in multiple
myeloma cells, and overcomes resistance to proteasome inhibitor bor-
tezomib [25]. 8TQ can suppress the proliferation of tumor cells in
culture [22]. As a derivative of 8TQ, capzimin exhibits higher se-
lectivity for PSMD14 over the related JAMM proteases and several
other metalloenzymes. According to a study, capzimin induced an un-
folded protein response and inhibited the proliferation and resistance of
cancer cells to bortezomib [16]. Herein, we evaluated the therapeutic
effects of OPA in malignant phenotypes of HCC cells and found that it
could significantly inhibit HCC growth and metastasis in vitro and in
vivo, indicating that targeting PSMD14 could serve as a potential
therapeutic modality for HCC.
In summary, the present study demonstrated that overexpression of
PSMD14 indicates the poor prognosis of patients with HCC, and
PSMD14-mediated GRB2 stabilization enhanced HCC growth and me-
tastasis. These findings provided the rationale for considering PSMD14
as a novel prognostic predictor and therapeutic target for HCC.
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Fig. 7. Therapeutic effects of PSMD14 inhibitor OPA on the malignant behavior of HCC cells.
A. The cytotoxicity of various concentrations of OPA to SMMC-7721 and Hep3B cells was examined by CCK-8 assay.
B. The cytotoxicity of various concentrations of OPA to SMMC-7721 and Hep3B cells was examined by colony formation assay.
C. SMMC-7721 and Hep3B cells were pre-treated with different concentrations of OPA for 48 h. A transwell assay was then conducted to examine the cell migration
and invasion. The representative images (up panel) and statistical results of the transwell assay.
D. Nude mice with tumors formed by SMMC-7721 cells were treated with vehicle control or OPA (30mg/kg; intraperitoneal (i.p.), 3 times each week) for 20 days.
E. The tumor weight of xenograft from different groups (D) was calculated.
F. SMMC-7721 cells were injected into the tail vein of nude mice. These nude mice were then treated with vehicle control or OPA (30 mg/kg; intraperitoneal (i.p.), 3
times each week). After 6 weeks, the representative microscopic images of pulmonary metastatic lesions were shown. The number of lung metastatic tumors in each
group was calculated. *p < 0.05, **p < 0.01, and ***p < 0.001. Data represent at least three independent experiments.
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